Dr. Anthony Fauci On Ivermectin is being used to help people against COVID-19 and variants: After people mocked those of us reporting about the inexpensive drugs

TheWhiteHouseSpin.Com

Wednesday, January 12, 2022

 

THE WHITE HOUSE

 

DR. ANTHONY FAUCI, DR. ROCHELLE WALENSKY AND JEFF ZIENTS BRIEFI THE WHITE HOUSE PRESSON TUESDAY, JANUARY 11, 2022. | WHITE HOUSE SNAPSHOT PHOTO BY KAREN ANN CARR / TheWhiteHouseSpin.Com.

 

 

 

White House COVID-19 Response Team and Public Health Officials of the United States of America

Reported by Karen Ann Carr

 

At 11:00 AM, virtual White House Press Briefing by White House COVID-19 Response Team and Public Health Officials on Wednesday, January 12, 2022.

 

The White House COVID-19 Response Team and Public Health Officials will provide updates on the COVID-19 response effort.

 

Participants will include:

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to President Biden

Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention

Jeff Zients, White House COVID-19 Response Coordinator

 

 

 

DR. ANTHONY FAUCI ON TUESDAY, JANUARY 11, 2022. | WHITE HOUSE SNAPSHOT PHOTO BY KAREN ANN CARR / TheWhiteHouseSpin.Com.

 

 

 

 

 

Officials of the United States of America

Reported by Karen Ann Carr

 

Dr. Fauci, announced today: Ivermectin is being used to help people against COVID-19 and variants. After people mocked those of us reporting about the inexpensive drug being used in Africa and around the world by Doctors and Medical workers.

 

After many of our lives-ones have gotten sick or worse are dead.

 

Heart-breaking because he pushed and is still pushing his Remdesivir that caused deaths in an Africa Study years ago and now at US Hospitals. Remdesivir is contributing to kidney failures and death due to retention of fluids in lungs etc. within a persons body. People drones in their own fluids that fill the lungs etc. Doctors and Scientist have been reporting.

 

****************************

Received from Pharmacist Dr. Wyniece Speed Harris "And the FDA should approve Novovax, pronto!!"

 

 

Immune responses included the following: Anti-spike IgG titers after Dose 3 increased 5.4-fold (prototype) to 9.3-fold (Omicron) from peak responses seen after 2-dose primary vaccination. This represents a 61.1-fold (prototype) and a 73.5-fold (Omicron) increase from prior to the Dose 3 boost.

IACE2-inhibition titers increased 6-fold (prototype) to 19.9-fold (Omicron) compared to peak responses following 2-dose primary series, representing a 54.4-fold (prototype), a 24.4-fold (Delta) and a 36.3-fold (Omicron) increase from prior to the booster.

 

Wild-type neutralization responses were observed after 2 doses for prototype, Delta and Omicron. Significant increases were observed after boosting, with titers for Delta and Omicron comparable to levels associated with protection in U.S. and Mexico and U.K. Phase 3 studies.

 

After 2 doses, Omicron wild-type neutralization was 4-fold lower than prototype, suggesting that both a booster dose as well as an Omicron-specific vaccine may be beneficial.

 

Further, data from the pediatric expansion of Novavax' PREVENT-19 Phase 3 trial in the U.S. and Mexico showed robust immune responses in adolescents, including increased IgG and receptor inhibition titers against a wide array of variants, including Omicron, following a 2-dose series. Responses in adolescents were 2- to 4-fold higher than adults against all evaluated variants.

 

"In the midst of an evolving pandemic, NVX-CoV2373 showed strong immune responses against Omicron and other circulating variants. We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants," said Gregory M. Glenn, President of Research and Development, Novavax. "Given the continued evolution of the coronavirus, the development of an Omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the Omicron spike protein vaccine and will soon enter the GMP-phase of production. We expect to begin clinical studies in the first quarter of 2022."

 

As part of an ongoing study, a single booster dose of 5 µg SARS-CoV-2 rS with 50 µg Matrix-M™ adjuvant was administered to healthy adult participants approximately six months after their primary 2-dose vaccination series. Multiple assays were used to evaluate immune responses against SARS-CoV-2 twenty-eight days following the booster dose.

 

Safety reporting of reactogenicity events showed an increasing trend across all 3 doses of NVX-CoV2373, reflecting the increased immunogenicity seen with a third dose. Following the booster, local and systemic reactions were generally short-lived with a median duration of approximately 2 days. The incidence of Grade 3 or higher events remained relatively low. Medically attended adverse events (MAAEs), potentially immune-mediated medical conditions (PIMMCs), and severe adverse events (SAEs) occurred infrequently following the booster dose and were balanced between vaccine and placebo groups.

 

The major findings, detailed in 'Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial,' will be submitted for peer-review publication and are expected to be available online at https://www.medrxiv.org/ in the coming days.

 

 

Conference Call Novavax will host a conference call for investors today at 4:30 p.m. ET. The dial-in numbers for the conference call are (877) 870-4263 (Domestic) or (412) 317-0790 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 7:30 p.m. ET on December 22, 2021 until 11:59 p.m. ET on December 31, 2021. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 6207101.

 

A webcast of the conference call can also be accessed on the Novavax website at novavax.com/events. A replay of the webcast will be available on the Novavax website until March 22, 2022.